XML 37 R26.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Income Taxes | 12 Months Ended
--- | ---
Dec. 31, 2024
Income Tax Disclosure [Abstract] |
Income Taxes | 15. Income Taxes During the years ended December 31, 2024, 2023 and 2022 the Company recorded an income tax (expense) benefit of $(2,751), $(3,860) and $(64), respectively. The December 31, 2024 and December 31, 2023 income tax provision is primarily due to foreign income taxes in Israel. The December 31, 2022 income tax provision is primarily due to foreign income taxes in Israel partially offset by losses in Ireland. For the years ended December 31, 2024, 2023 and 2022, the Company’s loss before income taxes is primarily generated in the United States as the pre-tax loss from the Company’s foreign subsidiaries is not significant. The components of our current and deferred portions of the provision for income taxes are presented in the table below:
|  | Years Ended December 31, |
|  | 2024 |  |  | 2023 |  |  | 2022 |
Current income tax (provision) benefit: |  |  |  |  |  |  |  |  |
Federal |  | $ | (40 | ) |  | $ | (237 | ) |  | $ | — |
State |  |  | (115 | ) |  |  | (167 | ) |  |  | (22 | )
Foreign |  |  | (2,847 | ) |  |  | (3,614 | ) |  |  | (3,256 | )
Total Current |  | $ | (3,002 | ) |  | $ | (4,018 | ) |  | $ | (3,278 | )
Deferred income tax (provision) benefit: |  |  |  |  |  |  |  |  |
Federal |  | $ | — |  |  | $ | — |  |  | $ | — |
State |  |  | — |  |  |  | — |  |  |  | — |
Foreign |  |  | 251 |  |  |  | 158 |  |  |  | 3,214 |
Total Deferred |  | $ | 251 |  |  | $ | 158 |  |  | $ | 3,214 |
Total provision for income taxes |  | $ | (2,751 | ) |  | $ | (3,860 | ) |  | $ | (64 | )
The following reconciles the differences between income taxes computed at the federal statutory rate and the provision for income taxes:
|  | Years Ended December 31, |
|  | 2024 |  |  | 2023 |  |  | 2022 |
Federal statutory income tax rate |  |  | 21.0 | % |  |  | 21.0 | % |  |  | 21.0 | %
State taxes, net of federal benefit |  |  | 0.0 |  |  |  | 1.1 |  |  |  | 3.7 |
Valuation allowance |  |  | (20.4 | ) |  |  | (7.1 | ) |  |  | (18.5 | )
Stock-based compensation |  |  | (2.3 | ) |  |  | (1.3 | ) |  |  | (5.1 | )
Permanent differences |  |  | (2.0 | ) |  |  | (14.0 | ) |  |  | (0.7 | )
Research and development credit |  |  | 5.3 |  |  |  | 0.0 |  |  |  | 0.0 |
Other |  |  | (2.9 | ) |  |  | (0.3 | ) |  |  | (0.4 | )
Effective income tax rate |  |  | (1.3 | )% |  |  | (0.6 | )% |  |  | — | %
Deferred tax assets and liabilities reflect the net tax effects of net operating loss and tax credit carryforwards and temporary differences between the carrying amount of assets and liabilities for financial reporting and the amounts used for tax purposes. Significant components of the Company's deferred tax assets and liabilities were as follows:
|  | As of December 31, |
|  | 2024 |  |  | 2023 |
Deferred tax assets: |  |  |  |  |  |
Net operating loss carryforwards |  | $ | 258,002 |  |  | $ | 229,264 |
Research and development credit carryforwards |  |  | 15,234 |  |  |  | 1,660 |
Deferred revenue |  |  | 298 |  |  |  | 2,687 |
Deferred compensation |  |  | 7,571 |  |  |  | 5,687 |
Leasing obligation |  |  | 2,138 |  |  |  | 3,087 |
Capitalized research expense |  |  | 45,670 |  |  |  | 43,476 |
Other |  |  | 3,736 |  |  |  | 2,415 |
Total deferred tax assets |  |  | 332,648 |  |  |  | 288,276 |
Total valuation allowance |  |  | 313,147 |  |  |  | 263,001 |
Total net deferred tax assets |  |  | 19,501 |  |  |  | 25,275 |
Joint venture investment basis difference |  |  | (841 | ) |  |  | (1,054 | )
Intangibles |  |  | (15,800 | ) |  |  | (20,879 | )
Right-of-use assets |  |  | (1,878 | ) |  |  | (2,738 | )
Other |  |  | (2,006 | ) |  |  | (1,902 | )
Total deferred tax assets (liabilities) |  |  | (20,525 | ) |  |  | (26,573 | )
Net deferred tax liabilities |  | $ | (1,024 | ) |  | $ | (1,298 | )
The Company has evaluated the positive and negative evidence bearing upon its ability to realize the deferred tax assets. Management has considered the Company's history of cumulative net losses incurred in the U.S. since inception and has concluded that it is more likely than not that the Company will not realize the benefits of the deferred tax assets. Accordingly, a full valuation allowance has been established against the net domestic deferred tax assets as of December 31, 2024, 2023 and 2022. Management reevaluates the positive and negative evidence at each reporting period. Changes in the valuation allowance for deferred tax assets during the years ended December 31, 2024, 2023 and 2022 related primarily to the increase in net operating loss carryforwards in 2024, 2023 and 2022 and were as follows:
|  | Years Ended December 31, |
|  | 2024 |  |  | 2023 |  |  | 2022 |
Valuation allowance as of beginning of the year |  | $ | 263,001 |  |  | $ | 214,776 |  |  | $ | 164,391 |
Increases recorded to income tax provision |  |  | 50,146 |  |  |  | 48,225 |  |  |  | 50,403 |
Decreases recorded as a benefit to income tax provision |  |  | — |  |  |  | — |  |  |  | (18 | )
Valuation allowance as of end of year |  | $ | 313,147 |  |  | $ | 263,001 |  |  | $ | 214,776 |
As of December 31, 2024, the Company has federal net operating loss carryforwards of approximately $985,956, which begin to expire in 2026. The Company’s federal net operating losses generated for the years ended after December 31, 2017, which amounted to a total of $757,416, can be carried forward indefinitely. The Company has tax effected state net operating losses of approximately $45,747, which began to expire in 2024. In addition, the Company has federal and state research and development tax credit carryforwards of $12,853 and $3,014, which begin to expire in 2027 and 2035, respectively. Utilization of the Company's net operating loss ("NOL") carryforwards and research and development ("R&D") credit carryforwards may be subject to a substantial annual limitation due to ownership change limitations that have occurred previously or that could occur in the future in accordance with Section 382 of the Internal Revenue Code of 1986 ("Section 382") as well as similar state provisions. These ownership changes may limit the amount of NOL and R&D credit carryforwards that can be utilized annually to offset future taxable income and taxes, respectively. In general, an ownership change as defined by Section 382 results from transactions increasing the ownership of certain shareholders or public groups in the stock of a corporation by more than 50% over a three-year period. Since its formation, the Company has raised capital through the issuance of capital stock on several occasions. These financings, combined with the purchasing shareholders' subsequent disposition of those shares, could result in a change of control as defined by Section 382. The Company conducted an analysis under Section 382 to determine if historical changes in ownership through December 31, 2021 would limit or otherwise restrict its ability to utilize its NOL and R&D credit carryforwards. As a result of this analysis, it was determined that $1,680 federal and $6,391 state net operating loss carryforwards generated through December 31, 2021 will expire unused. The Company also conducted an updated analysis under Section 382 to determine if historical changes in ownership through December 31, 2023 would limit or otherwise restrict its ability to utilize its NOL and R&D credit carryforwards. No changes were identified other than those noted in the prior Section 382 study completed as of December 31, 2021. Changes in ownership occurring after December 31, 2023, could affect the limitation in future years, and any limitation may result in expiration of a portion of the NOL or R&D credit carryforwards before utilization. The Company does no t have unrecognized tax benefits related to uncertain tax positions. The Company recognizes both accrued interest and penalties related to unrecognized tax benefits in income tax expense. The Company has not recorded any interest and penalties on any unrecognized tax benefits since its inception. The tax years 2006 through 2024 remain open to examination by major taxing jurisdictions to which the Company is subject, which is primarily in the United States (U.S.), as carryforward attributes generated in prior years may still be adjusted upon examination by the Internal Revenue Service (IRS) or state tax authorities if they have or will be used in a future period. The Company files income tax returns in the U.S. federal and various state jurisdictions. There are currently no federal or state audits in progress by the IRS or any other jurisdiction other than Israel for any tax years.

X
- References No definition available. + Details
Name: | us-gaap_IncomeTaxDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for income tax. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 270 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.5.Q1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/740/tableOfContent Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 11.C) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2 + Details
Name: | us-gaap_IncomeTaxDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration